Pharmacologic therapies for the management of non-neurogenic urinary incontinence in children

References

• Forsythe WI, Redmond A. Enuresis and spontaneous cure rate: study of 1129 enuretis. Arch Dis Child. 1974;49(4):259–263.
   PubMed Web of Science ®Google Scholar
• Van Herzeele C, Walle JV, Dhondt K, et al. Recent advances in managing and understanding enuresis. F1000Res. 2017 Oct 24;6: 1881
   PubMedGoogle Scholar
• Austin PF, Bauer SB, Bower W, et al. The standardization of terminology of lower urinary tract function in children and adolescents: update report from the standardization committee of the international children’s continence society. J Urol. 2014;191(6):1863–1865.
   PubMed Web of Science ®Google Scholar
• Abbott SM, Reid KJ, Zee PC. Circadian rhythm sleep-wake disorders. Psychiatr Clin North Am. 2015;38(4):805–823.
   PubMed Web of Science ®Google Scholar
• Dossche L, Wall JV, Van Herzeele C. The pathophysiology of monosymptomatic nocturnal enuresis with special emphasis on the circadian rhythm of renal physiology. Eur J Pediatr. 2016;175(6):747–754.
   PubMed Web of Science ®Google Scholar
• Caldwell PH, Edgard D, Hodson E, et al. Bedwetting and toileting problems in children. Med J Aust. 2005;182(4):190–195.
   PubMed Web of Science ®Google Scholar
• Kahraman A, Dursun H, Hatipoglu S, et al. Non-dipping phenomenon in children with monosymptomatic nocturnal enuresis. Pediatr Nephrol. 2013;28(7):1099–1103.
   PubMed Web of Science ®Google Scholar
• Caldwell PH, Sureshkumar P, Wong WC. Tricyclic and related drugs for nocturnal enuresis in children. Cochrane Database Syst Rev. 2016 Jan 20;1:CD002117.
   Google Scholar
• Vande Walle J, Stockner M, Raes A, et al. Desmopressin 30 years in clinical use: a safety review. Curr Drug Saf. 2007;2(3):232–238.
   PubMedGoogle Scholar
• Juul KV, Van Herzeele C, De Bruyne P, et al. Desmopressin melt improves response and compliance compared with tablet in treatment of primary monosymptomatic nocturnal enuresis. Eur J Pediatr. 2013;172(9):1235–1242.
   PubMed Web of Science ®Google Scholar
• Franco I, von Gontard A, De Gennaro M. International children’s continence society. Evaluation and treatment of monosymptomatic enuresis: a standardization document from the international children’s continence society. J Pediatr Urol. 2013;9(2):239–243.
   Web of Science ®Google Scholar
• Rang and Dali’s pharmacology, 7thed. 399–400. Edinburgh:Elsevier/Churchill Livingstone; 2011.
   Google Scholar
• Richardson DW, Robinson AG. Desmopressin. Ann Intern Med. 1985 Aug;103(2):228–239.
   PubMed Web of Science ®Google Scholar
• Highlights of prescribing information. Desmopressin Acetate. [cited 2019 May 10]. Available from: https://pdf.hres.ca/dpd_pm/00033156.PDF
   Google Scholar
• Callreus T, Lundahl J, Hoglund P, et al. Changes in the gastrointestinal motility influence the absorption of desmopressin. Eur J Clin Pharmacol. 1999;55(4):305–309.
   PubMed Web of Science ®Google Scholar
• De Guchtenaere A, Van Herzeele C, Raes A, et al. Oral lyophilizate formulation of desmopressin: superior pharmacodynamics compared to tablet due to low food interaction. J Urol. 2011;185(6):2308–2313.
   PubMed Web of Science ®Google Scholar
• Michelet R, Dossche L, De Bruyne P, et al. Effects of food and pharmaceutical formulation on desmopressin in pharmacokinetics in children. Clin Pharmacokinet. 2016;55(6):1159–1170.
   PubMedGoogle Scholar
• Michelet R, Dossche L, Van Herzeele C, et al. Claiming desmopressin therapeutic equivalence in children requires pediatric data: a population PKPD analysis. Eur J Clin Pharmacol. 2018;74(3):297–305.
   PubMed Web of Science ®Google Scholar
• Skoog SJ, Stokes A, Turner KL. Oral desmopressin: a randomized double-blind placebo controlled study of effectiveness in children with primary nocturnal enuresis. J Urol. 1997;158(3 pt 2):1035–1040.
   PubMed Web of Science ®Google Scholar
• Schulman SL, Stokes A, Salzman PM. The efficacy and safety of oral desmopressin in children with primary nocturnal enuresis. J Urol. 2001;166(6):2427–2431.
   PubMed Web of Science ®Google Scholar
• Glazener CM, Evans JH. Desmopressin for nocturnal enuresis in children. Cochrane DataBase Syst Rev. 2002;(3):CD002112.
   PubMedGoogle Scholar
• Chua ME, Silangcruz JM, Chang SJ, et al. Desmopressin withdrawal strategy for pediatric enuresis: A meta- analysis. Pediatrics. 2016;138(1):pii:e20160495. Epub 2016 Jun 24.
   Web of Science ®Google Scholar
• Rushton HG. Older pharmacologic therapy for nocturnal enuresis. Clin Pediatr (Phila). 1993 Jul; Spec No: 10–3
   Web of Science ®Google Scholar
• Deshpande AV, Caldwell PH. Medical management of nocturnal enuresis. Pediatr Drugs. 2012. 1. 14(2):71–77.
   PubMed Web of Science ®Google Scholar
• Neveus T, Eggert P, Evans J, et al. International children’s continence society. evaluation and treatment of monosymptomatic enuresis: a standardization document from the international children’s continence society. J Urol. 2010;183(2):441–447.
   PubMed Web of Science ®Google Scholar
• Bayne AP, Skoog SJ. Nocturnal enuresis: an approach to assessment and treatment. Pediatr Rev. 2014;35(8):327–334.
   PubMedGoogle Scholar
• Skoog SJ. Nocturnal enuresis: an approach to assessment and treatment. Pediatr Rev. 2014;35:327.
   PubMedGoogle Scholar
• Hunsballe JM, Rittig S, Pedersen EB, et al. Single dose imipramine reduces nocturnal urine output in patients with nocturnal enuresis and nocturnal polyuria. J Urol. 1997;158(3pt1):830–836.
   PubMedGoogle Scholar
• Rudorfer MV, Potter WZ. Metabolism of tricyclic antidepressants. Cell Mol Neurobiol. 1999;19(3):373–409.
   PubMed Web of Science ®Google Scholar
• DeVane CL, Savett M, Jusko WJ. Desipramine and 2-hydroxy-desipramine pharmacokinetics in normal volunteers. Eur J Clin Pharmacol. 1981;19(1):61–64.
   PubMed Web of Science ®Google Scholar
• Pollock BG, Perel JM. Hydroxy metabolites of tricyclic antidepressants: evaluation of relative cardiotoxicity. Psychopharmacol. 1989;7:232–236.
   Google Scholar
• Potter WZ, Manji HK. Antidepressants, metabolites, and apparent drug resistance. Clin Neuropharmacol. 1990;13(Suppl 1):S45–53.
   PubMedGoogle Scholar
• Smellie JM, McGrigor VS, Meadow SR, et al. Nocturnal enuresis: a placebo controlled trial of two antidepressant drugs. Arch Dis Child. 1996;75(1):62–66.
   PubMed Web of Science ®Google Scholar
• Prescribing information imipramine. [cited 2019 Sep 23]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/040903lbl.pdf
   Google Scholar
• Austin PF, Ferguson G, Yan Y, et al. Combination therapy with desmopressin and an anticholinergic medication for nonresponders to desmopressin for monosymptomatic nocturnal enuresis: a randomized, double-blind, placebo-controlled trial. Pediatr. 2008;122(5):1027–1032.
   PubMed Web of Science ®Google Scholar
• Park SJ, Park JM, Pai KS, et al. Desmopressin alone versus desmopressin and an anticholinergic in the first line treatment of primary monosymptomatic nocturnal enuresis: A multicenter study. Pediatr Nephrol. 2014;29(7):1195–1200.
   PubMed Web of Science ®Google Scholar
• Kazemi Rashed F, Nourizade D, Hajebrahimi S, et al. Does combination therapy with desmopressin and tolterodine improve the treatment outcomes of patients with monosymptomatic nocturnal enuresis? A randomized clinical controlled trial. ISRN Urol. 2013 Mar 25;2013:413146.
   PubMedGoogle Scholar
• Berkenwald A, Pires J, Ellsworth P. Evaluating use of higher dose oxybutynin in combination with desmopressin for refractory nocturnal enuresis. J Pediatr Urol. 2016;12(4):220.e1-6.
   PubMed Web of Science ®Google Scholar
• Azarfar A, Esmaeili M, Naseri M, et al. Comparison of combined treatment with desmopressin plus oxybutynin and desmopressin plus tolterodine in treatment of children with primary nocturnal enuresis. J Renal Injury Prev. 2015;4(3):80–86.
   PubMed Web of Science ®Google Scholar
• Neveus T, Tullus K. Tolterodine and imipramine in refractory enuresis: a placebo-controlled crossover study. Pediatr Nephrol. 2008;23(2):263–267.
   PubMed Web of Science ®Google Scholar
• Kajiwara M, Inoue K, Kato M, et al. Nocturnal enuresis and overactive bladder in children: an epidemiologic study. Int J Urol. 2006;13(1):36–41.
   PubMed Web of Science ®Google Scholar
• Chung JM, Lee SD, Kang DI, et al. Prevalence and associated factors of overactive bladder in Korean children 5–13 years old: A nationwide multicenter study. Urology. 2009;73:63–67.
   PubMed Web of Science ®Google Scholar
• Franco I. Overactive bladder in children. Nat Rev Urol. 2016 Sep;13(9):520–532. Epub 2016 Aug 17.
   PubMed Web of Science ®Google Scholar
• Veiga ML, Lordêlo P, Farias T, et al. Constipation in children with isolated overactive bladders. J Pediatr Urol. 2013;9(6 pt A):L 945–9.
   Web of Science ®Google Scholar
• Ramsay S, Bolduc S. Overactive bladder in children. Can Urol Assn J. 2017;11(1–2 suppl 1):S74–S79.
   PubMed Web of Science ®Google Scholar
• Coupland CAC, Hill T, Dening T, et al. Anticholinergic drug exposure and the risk of dementia. A nested case-control study. JAMA Intern Med. 2019 Jun 24;179: 1084.
   PubMed Web of Science ®Google Scholar
• Prescribing information, oxybutynin. [cited 2019 Sept 23]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/017577s034,018211s017,020897s018lbl.pdf
   Google Scholar
• Van Arendonk KJ, Knudson MJ, Austin JC, et al. Improved efficacy of extended release oxybutynin in children with persistent daytime urinary incontinence converted from regular oxybutynin. Urology. 2006;68(4):862–865.
   PubMed Web of Science ®Google Scholar
• Youdim K, Kogan BA. Preliminary study of the safety and efficacy of extended-release oxybutynin in children. Urology. 2002;59(3):428–432.
   PubMed Web of Science ®Google Scholar
• Reinberg Y, Crocker J, Wolpert J, et al. Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence. J Urol. 2003;169(1):317–319.
   PubMed Web of Science ®Google Scholar
• Gleason JM, Daniels C, Williams K, et al. Single center experience with oxybutynin transdermal system (patch) for management of symptoms related to non-neuropathic overactive bladder in children: an attractive well tolerated alternative form of administration. J Pediatr Urol. 2014;10(4):753–757.
   PubMed Web of Science ®Google Scholar
• Solifenacin pediatric data. [cited 2019 Sept 23]. Available from: https://www.fda.gov/media/107501/download
   Google Scholar
• Bolduc S, Moore K, Nadeau G, et al. Prospective open label study of solifenacin for overactive bladder in children. J Pediatr Urol. 2010;184(4 suppl):1668–1673.
   Google Scholar
• Nadeau G, Schroder A, Moore K, et al. Long-term use of solifenacin in pediatric patients with overactive bladder: extension of a prospective open-label study. Can Urol Assoc J. 2014;8(3–4):118–123.
   PubMed Web of Science ®Google Scholar
• Hoebeke P, De Pooter J, De Caestecker K, et al. Solifenacin for therapy resistant overactive bladder. J Urol. 2009;182(4 Suppl):2040–2044.
   PubMed Web of Science ®Google Scholar
• Newgreen D, Bosman B, Hollestein-Havelaar A, et al. Solifenacin in children and adolescents with overactive bladder: results of a phase 3 randomised clinical trial. Eur Urol. 2017;71(3):483–490.
   PubMed Web of Science ®Google Scholar
• Newgreen D, Bosman B, Hollestein-Havelaar A, et al. Long-term safety and efficacy of solifenacin in children and adolescents with overactive bladder. J Urol. 2017;198(4):928–936.
   PubMed Web of Science ®Google Scholar
• Lee SD, Chung JM, Kang DI, et al. Efficacy and tolerability of solifenacin 5mg fixed dose in Korean children with newly diagnosed idiopathic overactive bladder: a multicenter prospective study. J Korean Med Sci. 2017;32(2):329–334.
   PubMed Web of Science ®Google Scholar
• Detrol LA NDA. FDA. [cited 2019 Sept 23]. Available from: https://www.fda.gov/media/92542/download
   Google Scholar
• Nijman RJ, Borgstein NG, Ellsworth P, et al. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo-controlled trials. J Urol. 2005;173(4):1334–1339.
   PubMed Web of Science ®Google Scholar
• Kilic N, Balkan E, Akgoz S, et al. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability. Int J Urol. 2006;13(2):105–108.
   PubMed Web of Science ®Google Scholar
• Deng YJ, Ma G, Guo YF, et al. Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder. Zhongguo Dang Dai Er Ke Za Zhi. 2011;13(1):26–28.
   PubMedGoogle Scholar
• Babu R. Effectiveness of tolterodine in nonneurogenic voiding dysfunction. Indian Pediatr. 2006;43(11):980–983.
   PubMed Web of Science ®Google Scholar
• Hjalmas K, Hellstrom AL, Mogren K, et al. The overactive bladder in children: a potential future indication for tolterodine. BJU Int. 2001;87(6):569–574.
   PubMed Web of Science ®Google Scholar
• Munding M, Wessells H, Thornberry B, et al. Use of tolterodine in children with dysfunctional voiding: an initial report. J Urol. 2001;165(3):926–928.
   PubMed Web of Science ®Google Scholar
• Reinberg Y, Crocker J, Wolpert J, et al. Therapeutic efficacy of extended release oxybutynin chloride, and immediate release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence. J Urol. 2003;169(1):317–319.
   PubMed Web of Science ®Google Scholar
• Raes A, Hoebeke P, Segaert I, et al. Retrospective analysis of efficacy and tolerability of tolterodine in children with overactive bladder. Eur Urol. 2004;45(2):240–244.
   PubMed Web of Science ®Google Scholar
• Goessl C, Sauter T, Michael T, et al. Efficacy and tolerability of tolterodine in children with detrusor hyperreflexia. Urology. 2000;55(3):414–418.
   PubMed Web of Science ®Google Scholar
• Ayan S, Kaya K, Topsakal K, et al. Efficacy of tolterodine as a first-line treatment for nonneurogenic voiding dysfunction in children. BJU Int. 2005;96(3):411–414.
   PubMed Web of Science ®Google Scholar
• Nijman RJ, Borgstein NG, Ellsworth P, et al. Long-term tolerability of tolterodine extended release in children 5–11 years of age: results from a 12-month, open-label study. Eur Urol. 2007;52(5):1511–1516.
   PubMed Web of Science ®Google Scholar
• Ayan S, Topsakal K, Gokce G, et al. Efficacy of combined anticholinergic treatment and behavioral modification as a first line treatment for nonneurogenic and nonanatomical voiding dysfunction in children: a randomized controlled trial. J Urol. 2007;177(6):2325–2328.
   PubMed Web of Science ®Google Scholar
• Mahanta K, Medhi B, Kaur B, et al. Comparative efficacy and safety of extended-release and instant-release tolterodine in children with neural tube defects having cystometric abnormalities. J Pediatr Urol. 2008;4(2):118–123.
   PubMedGoogle Scholar
• Lopez Pereira P, Miguelez C, Caffarati J, et al. Trospium chloride for the treatment of detrusor instability in children. J Urol. 2003;170(5):1978–1981.
   PubMed Web of Science ®Google Scholar
• Malhotra B, El-Tahtawy A, Wang EQ, et al. Dose-escalating study of the pharmacokinetics and tolerability of fesoterodine in children with overactive bladder. J Pediatr Urol. 2012;8:336342.
   Web of Science ®Google Scholar
• Blais AS, Nadeau G, Moore K, et al. Prospective pilot study of mirabegron in pediatric patients with overactive bladder. Eur Urol. 2016;70(1):9–13.
   PubMed Web of Science ®Google Scholar
• Leon P, Jolly C, Binet A, et al. Botulinum toxin injections in the management of non-neurogenic overactive bladders in children. J Pediatr Surg. 2014;49(9):1424–1428.
   PubMed Web of Science ®Google Scholar
• Hoebeke P, De Caestecker K, Vande Walle J, et al. The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor. J Urol. 2006;176(1):328–331.
   PubMed Web of Science ®Google Scholar
• Blackburn SC, Jones C, Bedoya S, et al. Intravesical botulinum type-A toxin (Dysport) in the treatment of idiopathic detrusor overactivity in children. J Pediatr Urol. 2013;9(6 Pt A):750–753.
   PubMed Web of Science ®Google Scholar
• Marte A, Borrelli M, Sabatino MD, et al. Effectiveness of botulinum-A toxin for the treatment of refractory overactive bladder in children. Eur J Pediatr Surg. 2010;20(3):153–157.
   PubMed Web of Science ®Google Scholar
• Ucar M, Akgul AK, Parlak A, et al. Non-invasive evaluation of botulinum-A toxin treatment efficacy in children with refractory overactive bladder. Int Urol Nephrol. 2018;50(8):1367–1373.
   PubMed Web of Science ®Google Scholar
• Bayrak O, Sadioglu E, Sen H, et al. Efficacy of onabotulinum toxin A infection in pediatric patients with non-neurogenic detrusor overactivity. Neurourol Urodyn. 2017;36(8):2078–20782.
   PubMed Web of Science ®Google Scholar
• Lahdes-Vasama TT, Anttila A, Wahl E, et al. Urodynamic assessment of children treated with botulinum toxin A injections for urge incontinence: a pilot study. Scan J Urol Nephrol. 2011;45(6):397–400.
   PubMed Web of Science ®Google Scholar
• Greer T, Abbott J, Breytenbach W, et al. Ten years of experience with intravesical and intrasphincteric onabotulinumtoxinA in children. J Pediatr Urol. 2016;12(2):94.e1–6.
   PubMed Web of Science ®Google Scholar
• De Jonge GA. Enuresis risoria (giggle micturition). Ned Tijdschr Geneeskd. 1975;119:1335–1338.
   PubMedGoogle Scholar
• Logan BL, Blais S. Giggle incontinence: evolution of concept and treatment. J Pediatr Urol. 2017;13(5):430–435.
   PubMed Web of Science ®Google Scholar
• Leclair MD, Heloury Y. Non-neurogenic elimination disorders in children. J Pediatr Urol. 2010;6(4):338–345.
   PubMed Web of Science ®Google Scholar
• Cooper C. Giggle micturition. In: Kolvin I, Mackeith RC, Meadow SR, editors. Bladder control and enuresis. clinics in developmental medicine, No. 48 and 49. London: William Heinemann Ltd; 1973. p. 61–65.
   Google Scholar
• Berry AK, Zderic S, Carr M. Methylphenidate for giggle incontinence. J Urol. 2009;182(4 Suppl):2028–2032.
   PubMed Web of Science ®Google Scholar
• Azim E, Mobbs D, Jo B, et al. Sex differences in brain activation elicited by humor. Proc Natl Acad Sci USA. 2005 8;102(45):16496–16501.
   PubMed Web of Science ®Google Scholar
• Chandra M, Saharia R, Shi Q, et al. Giggle incontinence in children: a manifestation of detrusor instability. J Urol. 2002;168(5):2184–2187.
   PubMed Web of Science ®Google Scholar
• Palmer LS. Biofeedback in the management of urinary continence in children. Curr Urol Rep. 2010;11(2):122–127.
   PubMedGoogle Scholar
• Elzinga-Plomp A, Boemers TM, Messer AP, et al. Treatment of enuresis risoria in children by self-administered electric and imaginary shock. Br J Urol. 1995;76(6):775–778.
   PubMedGoogle Scholar
• Sher PK. Successful treatment of giggle incontinence with methylphenidate. Pediatr Neurol. 1994;10:81.
   PubMed Web of Science ®Google Scholar
• Sher PK, Reinberg Y. Successful treatment of giggle incontinence with methylphenidate. J Urol. 1996;156(2 Pt 2):656–658.
   PubMed Web of Science ®Google Scholar
• Prescribing information, Ritalin. [ cited 2019 Sep 23]. Available from: https://www.pharma.us.novartis.com/files/ritalin_ritalin-sr.pdf
   Google Scholar
• Chang JH, Lee KY, Kim TB, et al. Clinical and urodynamic effect of methylphenidate for the treatment of giggle incontinence (enuresis risoria). Neurourol Urodyn. 2011;30(7):1338–1342.
   PubMed Web of Science ®Google Scholar